NCT00739232已完成1 期
Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HSD-016 Administered Orally to Healthy Subjects
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 74 人开始时间: 2008年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 74
- 主要终点
- Safety and Tolerability
研究概览
简要总结
This is a single ascending dose study of HSD-016 to provide the initial assessment of the safety, tolerability, how the drug is absorbed and eliminated, and its effect on the body.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Active
Active Comparator
Active
干预措施: HSD-016 (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: placebo (Other)
结局指标
主要结局
Safety and Tolerability
时间窗: 3 months
次要结局
- Profiles of Drug Concentrations(3 months)
研究者
相似试验
已完成
1 期
Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of HSD-016Healthy SubjectsNCT00740649Wyeth is now a wholly owned subsidiary of Pfizer74
已完成
1 期
Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult SubjectsAllergyNCT01922661Regeneron Pharmaceuticals24
已完成
1 期
Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese SubjectsAlzheimer DiseaseHealthyNCT00684710Wyeth is now a wholly owned subsidiary of Pfizer56
已完成
1 期
Study Evaluating the Safety, Tolerability and Pharmacokinetics of NSA-789 in Healthy Japanese Male SubjectsHealthyNCT00619736Wyeth is now a wholly owned subsidiary of Pfizer56
已完成
1 期
Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy SubjectsHealthyNCT00550381Wyeth is now a wholly owned subsidiary of Pfizer72